Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.
Harding
S A
SA
Sarma
J
J
Din
J N
JN
Maciocia
P M
PM
Newby
D E
DE
Fox
K A A
KA
D018946:Chemokine CCL5 / Q000378:metabolism*; D000077144:Clopidogrel; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
D018946:Chemokine CCL5; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine